These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

732 related items for PubMed ID: 16933750

  • 1. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
    Khyriem AB, Sujatha S, Parija SC.
    Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
    [Abstract] [Full Text] [Related]

  • 2. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.
    Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y.
    J Antimicrob Chemother; 2004 Aug; 54(2):563-5. PubMed ID: 15254027
    [Abstract] [Full Text] [Related]

  • 3. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST, Tanty Haryanty T, Ng KP, Rohani MY, Hamimah H.
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [Abstract] [Full Text] [Related]

  • 4. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A, Pekmezović M, Barać A, Crnčević Radović L, Arsić Arsenijević V.
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [Abstract] [Full Text] [Related]

  • 5. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
    Manosuthi W, Sungkanuparph S, Thongyen S, Chumpathat N, Eampokalap B, Thawornwan U, Foongladda S.
    J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
    [Abstract] [Full Text] [Related]

  • 6. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya.
    Bii CC, Makimura K, Abe S, Taguchi H, Mugasia OM, Revathi G, Wamae NC, Kamiya S.
    Mycoses; 2007 Jan; 50(1):25-30. PubMed ID: 17302744
    [Abstract] [Full Text] [Related]

  • 7. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
    Chang WN, Huang CR, Lei CB, Lee PY, Chien CC, Chang HW, Chang CS, Lu CH.
    Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
    [Abstract] [Full Text] [Related]

  • 8. Current scenario of cryptococcosis and antifungal susceptibility pattern in India: a cause for reappraisal.
    Capoor MR, Mandal P, Deb M, Aggarwal P, Banerjee U.
    Mycoses; 2008 May; 51(3):258-65. PubMed ID: 18399907
    [Abstract] [Full Text] [Related]

  • 9. The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis.
    Wang H, Xu K, Liu L, Tan JP, Chen Y, Li Y, Fan W, Wei Z, Sheng J, Yang YY, Li L.
    Biomaterials; 2010 Apr; 31(10):2874-81. PubMed ID: 20044131
    [Abstract] [Full Text] [Related]

  • 10. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
    Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M.
    J Antimicrob Chemother; 2005 Dec; 56(6):1144-7. PubMed ID: 16282208
    [Abstract] [Full Text] [Related]

  • 11. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India.
    Khan ZU, Randhawa HS, Kowshik T, Chowdhary A, Chandy R.
    J Antimicrob Chemother; 2007 Aug; 60(2):312-6. PubMed ID: 17553813
    [Abstract] [Full Text] [Related]

  • 12. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
    Córdoba S, Isla MG, Szusz W, Vivot W, Altamirano R, Davel G.
    Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
    Schwarz P, Dromer F, Lortholary O, Dannaoui E.
    Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
    [Abstract] [Full Text] [Related]

  • 14. In vitro susceptibility of Cryptococcus gattii clinical isolates.
    Gomez-Lopez A, Zaragoza O, Dos Anjos Martins M, Melhem MC, Rodriguez-Tudela JL, Cuenca-Estrella M.
    Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
    [Abstract] [Full Text] [Related]

  • 15. Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil.
    Almeida AM, Matsumoto MT, Baeza LC, de Oliveira E Silva RB, Kleiner AA, Melhem Mde S, Mendes Giannini MJ, Laboratory Group on Cryptococcosis.
    FEMS Yeast Res; 2007 Jan; 7(1):152-64. PubMed ID: 17311593
    [Abstract] [Full Text] [Related]

  • 16. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
    Hai TP, Van AD, Ngan NTT, Nhat LTH, Lan NPH, Vinh Chau NV, Thwaites GE, Krysan D, Day JN.
    Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410
    [Abstract] [Full Text] [Related]

  • 17. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
    Yang F, Gritsenko V, Lu H, Zhen C, Gao L, Berman J, Jiang YY.
    Microbiol Spectr; 2021 Oct 31; 9(2):e0072321. PubMed ID: 34585947
    [Abstract] [Full Text] [Related]

  • 18. Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans.
    Shen J, Davis LE, Wallace JM, Cai Y, Lawson LD.
    Planta Med; 1996 Oct 31; 62(5):415-8. PubMed ID: 8923805
    [Abstract] [Full Text] [Related]

  • 19. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
    Schwarz P, Janbon G, Dromer F, Lortholary O, Dannaoui E.
    Antimicrob Agents Chemother; 2007 Jan 31; 51(1):383-5. PubMed ID: 17043122
    [Abstract] [Full Text] [Related]

  • 20. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
    Srimuang S, Prariyachatigul C, Chaiprasert A, Rungsipanuratn W, Tanphaichitra D.
    J Med Assoc Thai; 2000 Jan 31; 83(1):57-60. PubMed ID: 10710870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.